Femasys Inc (FEMY) Stock Price & Analysis

Femasys Inc (FEMY) fell 2.61% to USD 2.98 as of September 8, 2026 at 12:45 UTC, according to Nexqual real-time market data.

FEMY last closed at USD 2.98; the session ranged USD 2.93–3.06 on volume of 72,927 shares. Market capitalization is —, with a 52-week range of USD 2.02–22.2 (NCM). Source: Nexqual, September 8, 2026 at 12:45 UTC.

Key Statistics (as of September 8, 2026 at 12:45 UTC)

Technical Analysis (FEMY)

Nexqual's technical model rates FEMY "NEUTRAL" based on 2 bullish and 3 bearish signals across 128 daily candles, as of September 8, 2026 at 12:45 UTC.

From Femasys Inc's Latest SEC 10-K Filing (filed 2026-03-31)

Key Strengths & Strategy (as disclosed to the SEC)

• We have raised over $170 million since inception from both institutional and strategic investors, including Medtronic and executives from leading life science companies and our initial public offering, or IPO, in June 2021.   Our Intellectual Property and Production Capabilities   We have designed and developed the proprietary methods utilized in our women's health solutions so that they are protected by patents, know-how, and trade secrets.
• FDA-cleared and approved in Europe, UK, Canada, Israel and New Zealand.   FemBloc ® permanent birth control is a revolutionary first-in-class non-surgical solution, which involves minimally-invasive placement of a patented delivery system for precise delivery of our proprietary synthetic tissue adhesive (blended polymer) into both fallopian tubes simultaneously.
• Blocked fallopian tubes are necessary for successful permanent birth control, and FemChec offers significant advantages over other existing approaches, including use of existing ultrasound.   In June 2023 we received an IDE approval from the FDA to allow us to initiate the first phase of the pivotal trial for the FemBloc system followed by a confirmation test with FemChec (Clinicaltrials.gov NCT05977751).
• We estimate the immediately addressable U.S. market for FemaSeed, FemVue, a companion diagnostic product, and FemSperm, for in-office handling of sperm by the gynecologist, may be over $1 billion.   Execute on our clinical program to achieve FDA approval to advance our FemBloc system for use together with FemChec, our companion diagnostic device for ultrasound confirmation, as the preferred option for permanent birth control for women.

Partnerships

• Genetic testing of the eggs or embryo, also known as preimplantation genetic testing (PGT), is an often optional cost up to $10,000 or more if disorders are tested.
• We believe that we currently have sufficient capacity to meet clinical program demands, product supply and launch requirements for the FemaSeed and FemBloc products, both in the U.S. and in select international countries, and believe that we will be able to scale up our capacity relatively quickly with modest capital investment.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 12:45 UTC. This page is informational and not investment advice.